Antengene Corporation Limited (Antengene), a prominent global biopharmaceutical company, has announced a significant milestone: South Korea’s National Health Insurance Service (NHIS) has approved reimbursement for Xpovio (selinexor) starting July 1, 2024. This approval marks Xpovio’s inclusion in South Korea’s national reimbursed drugs list for treating adult patients with relapsed or refractory multiple myeloma (R/R MM).
Multiple myeloma (MM) is a challenging hematologic malignancy characterized by abnormal plasma cell proliferation, with high relapse rates and limited treatment options. The global MM market is substantial, surpassing US$ 17 billion in 2023 and projected to grow to US$ 26 billion by 2028, reflecting a compound annual growth rate (CAGR) of 8.7%.
Xpovio stands out as the world’s first orally-available, selective XPO1 inhibitor, leveraging a novel mechanism of action. It has garnered approvals in over 40 countries and regions worldwide, enhancing its global presence.
Antengene is advancing Xpovio’s accessibility across Asia-Pacific (APAC), having already secured health insurance coverage in mainland China, Australia, and Singapore. The NHIS approval in South Korea underscores Xpovio’s potential to deliver significant clinical benefits to more patients grappling with R/R MM.
Antengene has submitted New Drug Applications (NDAs) for Xpovio in Thailand, Malaysia, and Indonesia, targeting both R/R MM and relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Xpovio’s unique mechanism involves inhibiting the XPO1 protein, promoting the accumulation and activation of tumor suppressor proteins while reducing oncogenic protein levels. This approach supports its use in various combination therapies, currently under investigation in clinical trials across China for hematologic malignancies and solid tumors.
Antengene remains committed to its mission of developing innovative therapies that transcend borders, aiming to redefine treatment standards for patients facing hematologic malignancies and solid tumors globally.